St. Joseph, Missouri, February 6, 2012 – Teva Animal Health today announced that it will resume the manufacture and distribution of non sterile liquid products, after receiving approval to do so from the Food and Drug Administration.

Teva Animal Health received approval to resume manufacturing, processing, packing, labeling, holding and distributing non sterile animal liquid products. The firm manufactures proprietary and generic drug products to the US animal health market.

“We are pleased to receive this news from FDA,” said Dave Cunningham, President & CEO of Teva Animal Health.

“I am extremely proud of the hard work and dedication of our employees as we have been working non-stop to resume operations at this facility and this is the next step to that end,” Cunningham said in a news release.

The FDA found violations at the facility in 2009 and shut down production.

The Israeli company bought IVX Animal Health in St Joseph in 2006, and has since invested heavily in improvements here.